MA49059A - Traitement des cancers positifs à her2 - Google Patents
Traitement des cancers positifs à her2Info
- Publication number
- MA49059A MA49059A MA049059A MA49059A MA49059A MA 49059 A MA49059 A MA 49059A MA 049059 A MA049059 A MA 049059A MA 49059 A MA49059 A MA 49059A MA 49059 A MA49059 A MA 49059A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- positive her2
- cancers
- her2 cancers
- positive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491872P | 2017-04-28 | 2017-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49059A true MA49059A (fr) | 2021-03-24 |
Family
ID=62165692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049059A MA49059A (fr) | 2017-04-28 | 2018-04-27 | Traitement des cancers positifs à her2 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11207324B2 (fr) |
| EP (1) | EP3615067A1 (fr) |
| JP (2) | JP7328151B2 (fr) |
| KR (1) | KR102845148B1 (fr) |
| CN (1) | CN111032082B (fr) |
| AU (2) | AU2018258663B2 (fr) |
| BR (1) | BR112019022280A2 (fr) |
| CA (1) | CA3060407A1 (fr) |
| EA (1) | EA201992573A1 (fr) |
| MA (1) | MA49059A (fr) |
| SG (1) | SG11201909676WA (fr) |
| WO (1) | WO2018201016A1 (fr) |
| ZA (1) | ZA201907225B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102845148B1 (ko) | 2017-04-28 | 2025-08-20 | 씨젠 인크. | Her2 양성 암의 치료 |
| TW202042820A (zh) * | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
| AU2019450366B2 (en) * | 2019-06-11 | 2026-01-08 | Board Of Regents, The University Of Texas System | Use of an RXR agonist in treating Her2+ cancers |
| CA3156820A1 (fr) * | 2019-10-21 | 2021-04-29 | Seagen Inc. | Methodes de traitement du cancer du sein her2 positif avec du tucatinib en association avec de la capecitabine et du trastuzumab |
| AU2020381495A1 (en) * | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| WO2021243123A1 (fr) * | 2020-05-29 | 2021-12-02 | Seagen Inc. | Procédés de traitement du cancer positif her2 au moyen de tucatinib en combinaison avec du trastuzumab et une chimiothérapie à base d'oxaliplatine |
| CA3189333A1 (fr) * | 2020-07-29 | 2022-02-03 | Seagen Inc. | Procedes de traitement d'un cancer her2 positif au moyen de tucatinib en association avec du trastuzumab, un taxane et un antagoniste du vegfr-2 |
| IL301405A (en) * | 2020-09-28 | 2023-05-01 | Seagen Inc | Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| US11526994B1 (en) * | 2021-09-10 | 2022-12-13 | Neosoma, Inc. | Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images |
| WO2024183622A1 (fr) * | 2023-03-03 | 2024-09-12 | 盛禾(中国)生物制药有限公司 | Utilisation d'un anticorps anti-her2 dans la préparation d'un médicament pour le traitement du cancer |
| WO2025132522A1 (fr) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Polythérapide anticancéreuse |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993017668A1 (fr) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Microspheres a liberation regulee contenant l'hormone adrenocorticotrope (acth) |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| KR101028952B1 (ko) | 2003-08-14 | 2011-04-12 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| EP1768963A4 (fr) | 2004-06-03 | 2009-06-10 | Smithkline Beecham Cork Ltd | Procede de traitement du cancer |
| KR101086967B1 (ko) | 2005-11-15 | 2011-11-29 | 어레이 바이오파마 인크. | 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물 |
| WO2009042618A1 (fr) | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Thérapies pour traiter le cancer en utilisant des combinaisons d'inhibiteurs de cox-2 et des anticorps anti-her2(erbb2) ou des combinaisons d'inhibiteurs de cox-2 et des inhibiteurs du récepteur her2(erbb2) de la tyrosine kinase |
| HUE035184T2 (en) | 2008-03-18 | 2018-05-02 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| KR101806323B1 (ko) * | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| JP6468838B2 (ja) * | 2011-05-19 | 2019-02-13 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 |
| JP5944514B2 (ja) | 2011-10-14 | 2016-07-05 | アレイ バイオファーマ、インコーポレイテッド | 固体分散体 |
| RU2629116C2 (ru) | 2011-10-14 | 2017-08-24 | Эррэй Биофарма Инк. | Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их |
| NZ756264A (en) | 2012-03-23 | 2022-09-30 | Array Biopharma Inc | Treatment of brain cancer |
| CA2955384C (fr) * | 2014-07-17 | 2024-03-12 | Biocurity Holdings, Inc. | Traitement du cancer associant un rayonnement, des nanoparticules d'oxyde de cerium et un agent chimiotherapeutique |
| US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2017184775A1 (fr) * | 2016-04-19 | 2017-10-26 | The Regents Of The University Of California | Inhibiteurs de erbb et leurs utilisations |
| KR102845148B1 (ko) | 2017-04-28 | 2025-08-20 | 씨젠 인크. | Her2 양성 암의 치료 |
| WO2019241599A1 (fr) | 2018-06-14 | 2019-12-19 | Memorial Sloan Kettering Cancer Center | Méthodes de prédiction de la réactivité de patients atteints d'un cancer du poumon à des thérapies ciblant her2 |
| TW202042820A (zh) | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
| CA3156820A1 (fr) | 2019-10-21 | 2021-04-29 | Seagen Inc. | Methodes de traitement du cancer du sein her2 positif avec du tucatinib en association avec de la capecitabine et du trastuzumab |
| AU2020381495A1 (en) | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| JP2023517078A (ja) | 2020-03-11 | 2023-04-21 | シージェン インコーポレイテッド | ツカチニブを用いてｈｅｒ２突然変異を有するがんを処置する方法 |
-
2018
- 2018-04-27 KR KR1020197035001A patent/KR102845148B1/ko active Active
- 2018-04-27 CA CA3060407A patent/CA3060407A1/fr active Pending
- 2018-04-27 SG SG11201909676W patent/SG11201909676WA/en unknown
- 2018-04-27 EA EA201992573A patent/EA201992573A1/ru unknown
- 2018-04-27 EP EP18724716.8A patent/EP3615067A1/fr active Pending
- 2018-04-27 AU AU2018258663A patent/AU2018258663B2/en active Active
- 2018-04-27 CN CN201880043831.3A patent/CN111032082B/zh active Active
- 2018-04-27 US US16/607,850 patent/US11207324B2/en active Active
- 2018-04-27 MA MA049059A patent/MA49059A/fr unknown
- 2018-04-27 JP JP2019558369A patent/JP7328151B2/ja active Active
- 2018-04-27 WO PCT/US2018/029899 patent/WO2018201016A1/fr not_active Ceased
- 2018-04-27 BR BR112019022280A patent/BR112019022280A2/pt unknown
-
2019
- 2019-10-30 ZA ZA2019/07225A patent/ZA201907225B/en unknown
-
2021
- 2021-11-18 US US17/530,265 patent/US11666572B2/en active Active
-
2022
- 2022-09-28 AU AU2022241509A patent/AU2022241509B2/en active Active
-
2023
- 2023-04-26 US US18/139,653 patent/US12048698B2/en active Active
- 2023-08-03 JP JP2023126666A patent/JP2023145689A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200014298A (ko) | 2020-02-10 |
| ZA201907225B (en) | 2023-11-29 |
| JP7328151B2 (ja) | 2023-08-16 |
| SG11201909676WA (en) | 2019-11-28 |
| KR102845148B1 (ko) | 2025-08-20 |
| US11666572B2 (en) | 2023-06-06 |
| EA201992573A1 (ru) | 2020-04-06 |
| AU2022241509B2 (en) | 2025-02-20 |
| JP2023145689A (ja) | 2023-10-11 |
| JP2020517696A (ja) | 2020-06-18 |
| US20200188401A1 (en) | 2020-06-18 |
| US12048698B2 (en) | 2024-07-30 |
| CA3060407A1 (fr) | 2018-11-01 |
| AU2022241509A1 (en) | 2022-10-27 |
| CN111032082A (zh) | 2020-04-17 |
| US20220168303A1 (en) | 2022-06-02 |
| AU2018258663A1 (en) | 2019-11-14 |
| AU2018258663B2 (en) | 2022-08-04 |
| US11207324B2 (en) | 2021-12-28 |
| BR112019022280A2 (pt) | 2020-05-19 |
| EP3615067A1 (fr) | 2020-03-04 |
| CN111032082B (zh) | 2025-01-07 |
| US20230390290A1 (en) | 2023-12-07 |
| WO2018201016A1 (fr) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49059A (fr) | Traitement des cancers positifs à her2 | |
| EP3488001A4 (fr) | Traitement du cancer | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA43374A (fr) | Méthodes de traitement de tumeurs malignes | |
| EP3388004A4 (fr) | Instrument de traitement | |
| EP3370721A4 (fr) | Traitement de l'ostéoarthrite | |
| PL3580211T3 (pl) | 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3592428A4 (fr) | Induction optogénétique de pathologies neurodégénératives | |
| EP3261641A4 (fr) | Traitement de la pancréatite | |
| PL3377516T3 (pl) | Kompozycja do leczenia nowotworu | |
| MA47408A (fr) | Traitement du cancer | |
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| PT3622953T (pt) | Tratamento combinado do cancro | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| IL258521B1 (en) | Combination therapy for the treatment of cancer | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| LT3576740T (lt) | Vėžio gydymas | |
| EP3606531A4 (fr) | Méthodes de traitement du cancer | |
| MA46361A (fr) | Traitement du cancer de la prostate | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| PL3525774T3 (pl) | Leczenie lazofoksyfenem raka piersi er+ | |
| MA52627A (fr) | Traitement du cancer |